



Mangion, K., Carrick, D., Payne, A., McClure, J., Mason, M., Petrie, M., McEntegart, M., Eteiba, H., Oldroyd, K., and Berry, C. (2015) Infarct burden following multivessel PCI vs. infarct-only PCI in patients with acute STEMI: the Glasgow PRAMI CMR sub-study. *Journal of Cardiovascular Magnetic Resonance*, 17(Sup 1), O9.

Copyright © 2015 The Authors

This work is made available under the Creative Commons Attribution 4.0 License (CC BY 4.0)

Version: Published

<http://eprints.gla.ac.uk/104599>

Deposited on: 01 April 2015

ORAL PRESENTATION

Open Access

Infarct burden following multivessel PCI vs. infarct-only PCI in patients with acute STEMI: the Glasgow PRAMI CMR sub-study

Kenneth Mangion^{1*}, David Carrick², Alexander R Payne², John D McClure¹, Maureen Mason², Mark Petrie², Margaret McEntegart², Hany Eteiba², Keith G Oldroyd², Colin Berry¹

From 18th Annual SCMR Scientific Sessions
Nice, France. 4-7 February 2015

Background

In the Preventive Angioplasty in Myocardial Infarction trial (PRAMI; ISRCTN73028481), immediate multivessel PCI (MV-PCI) of non-IRA (infarct related artery) lesions in patients with acute ST elevation myocardial infarction (STEMI) and multivessel coronary disease (MVD) improved long term prognosis. We assessed infarct distribution and size in a pre-specified cardiac magnetic resonance (CMR) sub-study.

Methods

In this single centre prospective sub-study, PRAMI participants were invited to undergo 1.5 Tesla CMR 1 week and 1 year after primary PCI. The CMR scans were analysed using semi-automated software by a clinician blinded to treatment group assignment and clinical outcomes. The

presence and extent of infarction were assessed quantitatively with late gadolinium enhancement (LGE) imaging (Gadovist, 0.1 mmol/kg). The infarct was delineated as an area of myocardial enhancement (cm²) using a signal intensity threshold of >5SDs above a remote region, and expressed as a % of total LV mass. The incidence of new LGE in non-infarct related artery territories at baseline and 1 year were assessed. Data were analysed by an independent statistician.

Results

Of 465 randomised trial participants in 6 UK hospitals, 138 (30%) were enrolled in Glasgow. Of these 80 patients underwent CMR 1 week post primary PCI of whom 41 (51%) were in the multi-vessel PCI group and 39 (49%) were in the IRA-only group. At 1 year,

Table 1 Infarct size and distribution in non-infarct artery territory in the randomised PRAMI trial participants (n=80) in Glasgow

	Infarct-only PCI n = 39 (49%)	Multivessel PCI n=41 (51%)	p
1 week post-MI			
Infarct size, % LV [†]	16.9 (14.0)	13.9 (12.1)	0.32
Infarct in non-IRA territory, n (%)	0 (0)	0 (0)	1.00
1 year post-MI			
Infarct size, % LV	13.9 (10.1)	11.1 (11.2)	0.20
Change in infarct size from baseline, % LV mass*	-2.23 (-9.97, 0.56)	-1.73 (-7.10, 0.94)	0.60
Infarct in non-IRA territory, n (%)	2 (5.1)	3 (7.3)	1.00

[†] mean (standard deviation)

*median (interquartile range)

¹BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK

Full list of author information is available at the end of the article

69 (86%) patients had a follow up CMR scan. Infarct size and distribution are described in Table 1.

Conclusions

Infarct size and distribution were similar in patients treated by MV-PCI or IRA-only PCI. MV-PCI is not associated with additional MI acutely which supports the safety of this procedure in line with the benefits observed with preventive PCI in PRAMI.

Funding

Golden Jubilee National Hospital; PRAMI was funded by Barts and the London Charity.

Authors' details

¹BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. ²Golden Jubilee National Hospital, Clydebank, UK.

Published: 3 February 2015

doi:10.1186/1532-429X-17-S1-O9

Cite this article as: Mangion *et al.*: Infarct burden following multivessel PCI vs. infarct-only PCI in patients with acute STEMI: the Glasgow PRAMI CMR sub-study. *Journal of Cardiovascular Magnetic Resonance* 2015 **17**(Suppl 1):O9.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

